Dersimelagon rights acquired by LEO Pharma
LEO Pharma agreed to acquire Dersimelagon rights, a Denmark / Japan therapeutics brand on Aug 18, 2026. FundComb records estimated consideration of USD 435m. Public sources confirm the deal; valuation inputs may include estimates where transaction materials do not disclose the full economics.
Transaction summary
- Target
- Dersimelagon rights
- Acquirer
- LEO Pharma
- Seller
- Tanabe Pharma
- Announced
- 2026-08-18
- Geography
- Denmark / Japan
- Tags
- DermatologyPharmaRare DiseaseTherapeutics
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-09-11
- Latest update
- 2026-09-16
Value and multiples
Price / value
USD 435M
Consideration | USD
Basis: Estimated
EV / revenue
-
Period not stated
Basis: FundComb estimate
EV / EBITDA
-
EBITDA basis not stated
Basis: FundComb estimate
Basis
- USD 435m consideration is a FundComb estimate. Public sources reviewed confirm the transaction, but do not independently disclose every valuation input.
Source summary
Leo Pharma buys rare skin disease drug in $435M deal
ConfirmedBioPharma Dive reports that LEO Pharma will acquire rights to Tanabe Pharma's late-stage dersimelagon, with up to $435 million in upfront and near-term milestone payments plus contingent royalties.
Open sourceLeo Pharma buys rare skin disease drug in $435M deal
ConfirmedLeo Pharma buys rare skin disease drug in $435M deal | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xtelligent Pharma Life Sciences Explore our brands An Informa TechTarget Publication Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search People also ask Loading questions... Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Dive Brief Leo Pharma buys rare skin disease drug in $435M deal Tanabe Pharma has already asked the FDA to approve the medicine for two conditions that cause severe reactions to sunlight. Published Aug. 18, 2026 By Kristin Jensen Share Copy link Email LinkedIn X/Twitter Facebook Print License Add us on Google Getty Images Dive Brief: Leo Pharma on Tuesday said it
Open sourceLEO Pharma agreement to acquire dersimelagon rights
ConfirmedLEO Pharma dated its agreement announcement 18 August 2026. The transaction concerns worldwide drug rights, includes an upfront and near-term milestone ceiling of USD 435 million, and remains subject to closing conditions. No equity ownership percentage is disclosed.
Open source